1. Home
  2. FT vs CRVS Comparison

FT vs CRVS Comparison

Compare FT & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Universal Trust

FT

Franklin Universal Trust

HOLD

Current Price

$8.05

Market Cap

202.6M

Sector

Finance

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$7.48

Market Cap

634.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FT
CRVS
Founded
1988
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
202.6M
634.0M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
FT
CRVS
Price
$8.05
$7.48
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$13.75
AVG Volume (30 Days)
63.0K
1.6M
Earning Date
01-01-0001
11-04-2025
Dividend Yield
7.85%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.97
$2.54
52 Week High
$7.23
$9.60

Technical Indicators

Market Signals
Indicator
FT
CRVS
Relative Strength Index (RSI) 57.60 39.21
Support Level $7.80 $7.34
Resistance Level $7.91 $8.00
Average True Range (ATR) 0.09 0.53
MACD 0.01 -0.15
Stochastic Oscillator 79.71 6.19

Price Performance

Historical Comparison
FT
CRVS

About FT Franklin Universal Trust

Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Share on Social Networks: